Needham Maintains Buy on Conmed, Raises Price Target to $129
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson maintains a Buy rating on Conmed (NYSE:CNMD) and raises the price target from $119 to $129.
February 01, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a Buy rating on Conmed and raises the price target from $119 to $129.
The increase in price target by a reputable analyst suggests a positive outlook on Conmed's stock, likely leading to a short-term increase in its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100